Trastuzumab pamirtecan represents a potentially practice-changing therapy in recurrent endometrial cancer, a space with few effective options. With Breakthrough Therapy designation and strong Phase 2 data across HER2 expression levels, the path toward BLA filing in 2026 enhances near-term catalyst potential. Traders should monitor upcoming regulatory interactions and Phase 3 readouts, particularly DYNASTY-Breast02 later this year.
Price Chart
Executive Summary
BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in advanced endometrial cancer, showing a 47.9% confirmed objective response rate and 8.1-month median progression-free survival across all HER2 expression levels, with a manageable safety profile. The data support the drug's potential in a high-unmet-need population, including those with prior checkpoint inhibitor exposure.
Key Facts
- Phase 2 cohort of 145 patients with advanced HER2-expressing endometrial cancer met primary endpoint of objective response rate (ORR).
- Confirmed ORR was 47.9% in centrally tested patients (n=96), with 49.3% in those previously treated with checkpoint inhibitors.
- Median progression-free survival was 8.1 months (95% CI: 5.5, 11.8) in centrally tested patients.
- Trastuzumab pamirtecan showed activity across all HER2 expression levels (IHC1+, IHC2+, IHC3+) and in real-world populations including those with visceral metastases.
- Safety profile was manageable; grade ≥3 treatment-related adverse events occurred in 46.9% of patients, with 4.8% experiencing grade ≥3 ILD/pneumonitis.
- FDA has granted Fast Track and Breakthrough Therapy designations for this indication; BLA submission planned in 2026 pending regulatory feedback.
- Global Phase 3 trial (Fern-EC-01) is ongoing, with plans to file BLA subject to FDA input.
Financial Impact
High-value oncology pipeline advancement with registrational potential; could expand BNTX's market beyond mRNA into targeted cancer therapies.
Risk Factors
- Phase 2 data may not be replicated in larger Phase 3 trials.
- Safety signals, including 4.8% grade ≥3 ILD/pneumonitis, could impact regulatory or commercial acceptance.
- Dependence on successful collaboration with DualityBio for development and commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272109 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.51 (−2.38%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.51 (−2.38%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.51 (+5.45%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.51 (−12.97%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.51 (+4.00%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.51 (−5.65%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.51 (+4.62%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.51 (+4.62%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.51 (+3.94%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.51 (+12.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access